Coda Octopus (CODA) Q2 2026 Earnings Transcript

Coda Octopus reported Q2 revenue of $6.9 million, down 1.6%, but earnings quality improved materially with gross profit rising to $4.6 million, operating income up 64.8% to $1.8 million, and net income increasing to $1.7 million, or $0.15 per diluted share. The decline in Marine Technology revenue was driven by Middle East and Asia demand disruption tied to Iran/Strait of Hormuz instability, while higher rental revenue, stronger Defense Engineering Services, and FX benefits supported margins. Management also highlighted a major milestone as the DAVID untethered system was approved for Navy use, initial NanoGen orders were received, and two M&A opportunities are under due diligence.

Analysis

The key inflection is not the modest top-line decline; it is that CODA is converting geopolitical noise into a higher-quality revenue mix. Rental utilization plus lower commission drag materially improved segment economics, which means the business can expand margins even before demand normalizes. That matters because the market will likely underwrite the recent margin step-up as cyclical when part of it is actually structural if rental becomes a larger share of deployed systems.

The bigger second-order catalyst is the transition of DAVID from “trialware” to a procurement object. Navy-use approval removes the gating item that suppresses budgets, but the more important implication is that fielded units now create an internal reference case inside a conservative buyer with long sales cycles. If even a small fraction of the previously purchased systems get reallocated into active use, it can create follow-on orders without needing a formal IDIQ structure, which is a better setup for recurring direct sales than one-off pilot revenue.

The market may be missing how asymmetric NanoGen is relative to current financials: today it is immaterial, but once a platform integration is locked, the revenue can recur over a program’s build cycle rather than a single quarter. That makes the near-term revenue bridge less important than the design-win cadence over the next 6-12 months. The contrarian risk is that management is probably right that the Middle East weakness is “timing, not structural,” but timing can still be a multiple compressor if stabilization slips into FY27.

From a capital allocation perspective, the company now has three shots on goal: defense adoption, M&A, and margin comp. The balance sheet gives them optionality, but any deal will be judged against the opportunity cost of buying back or investing internally into the sonar pipeline. If they acquire a low-growth asset simply to fill revenue, the market will likely penalize the stock despite the cash-rich position.

Key Decisions for Investors

• Long CODA common on weakness for a 3-6 month hold: the setup favors multiple expansion if DAVID follow-on orders arrive in Q3/Q4; downside is limited by cash and no debt, but position size should stay modest because revenue visibility is still low.
• Buy CODA Jan-2027 calls or call spreads to express the design-win optionality in NanoGen and DAVID without taking full downside from geopolitical timing risk; best risk/reward if the stock rerates on contract headlines rather than near-term earnings.
• Pair trade: long CODA / short a defense prime or marine-equipment name with slower margin conversion; CODA has better operating leverage and cleaner balance sheet, but this only works if you expect direct procurement momentum over the next 2 quarters.
• Avoid chasing after any M&A announcement until the asset mix is clear; if they buy growth dilution, fade the first pop, because the core valuation thesis depends on internal product adoption rather than financial engineering.